China Cardiovascular Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The China Cardiovascular Devices Market Report is Segmented by Device Type (Diagnostic & Monitoring Devices, Therapeutic & Surgical Devices), Application (Coronary Artery Disease, Arrhythmia & Conduction Disorders, Heart Failure & Cardiomyopathy, and More), End-User (Hospitals & Cardiac Centres, Ambulatory Surgical Centres, and More). The Market Forecasts are Provided in Terms of Value (USD).

China Cardiovascular Devices Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
View Global Report

Compare market size and growth of China Cardiovascular Devices Market with other markets in Healthcare Industry

China Cardiovascular Devices Market Analysis by Mordor Intelligence

The China cardiovascular devices market size stands at USD 3.16 billion in 2025 and is forecast to reach USD 4.19 billion by 2030, advancing at a 5.79% CAGR over the period. Rising life expectancy, an estimated 330 million cardiovascular patients, and the policy tilt of “Healthy China 2030” continue to lift procedure volumes and the uptake of both interventional and monitoring technologies . Price compression sparked by volume-based procurement (VBP) on coronary stents triggered a 95% price fall yet lifted overall stent usage by nearly 10%, illustrating how cost reform can amplify device penetration. Domestic producers are capitalising on these reforms, aided by “Made in China 2025,” which targets 70% local production of mid- to high-end cardiovascular equipment by 2025 . Simultaneously, China’s expanding chest-pain-center network has cut median door-to-balloon times from 117.7 minutes to 46.9 minutes, adding momentum to advanced imaging, guidewire, and emergency monitoring demand.

Key Report Takeaways

  • By device type, Therapeutic and Surgical Devices led with 68.20% of the China cardiovascular devices market share in 2024, while Diagnostic and Monitoring Devices are projected to log the fastest 6.98% CAGR through 2030.
  • By application, Coronary Artery Disease commanded 46.50% of the China cardiovascular devices market size in 2024, whereas Structural and Congenital Heart Defects are set to expand at a 7.14% CAGR to 2030.
  • By end-user, hospitals and cardiac centers retained 72.49% share of the China cardiovascular devices market in 2024, but home-care settings are forecast to grow at a 6.78% CAGR over 2025-2030.

Segment Analysis

By Device Type: Domestic innovation disrupts traditional hierarchies

Therapeutic and Surgical Devices contributed 68.20% of the China cardiovascular devices market in 2024, buoyed by 2,200 annual coronary interventions at leading centers and VBP-induced volume surges. The cardiac-rhythm-management niche accelerated after NMPA cleared MicroPort Sorin’s new pacing lead in February 2025, underscoring local progress in hermetic sealing and lead-coil metallurgy. Intravascular lithotripsy, renal denervation, and next-gen drug-coated balloons form the emerging wave, with localisation tipping cost-of-goods lower than imports. Over the forecast period, domestic innovators are expected to keep displacing foreign incumbents across mid-complexity implants, reinforcing the primacy of this category within the China cardiovascular devices market.

Diagnostic and Monitoring Devices are projected to expand at a 6.98% CAGR through 2030. AI-enabled ECG analytics integrated into smart wearables bring early detection into homes, while hospital chest-pain networks still buy high-throughput CT and MRI scanners for triage optimisation. Cardiac-biomarker assays backed by local reagent makers support rapid rule-out protocols, serving the 330 million strong patient pool . Cloud-native data platforms align with the NMPA’s revised cybersecurity guidance, helping vendors secure faster approval for software-as-medical-device modules. Given rising chronic-disease management at home, connected diagnostics should keep edging wallet share away from purely interventional SKUs, adding depth to the China cardiovascular devices market size.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By Application: Structural heart defects emerge as growth frontier

Coronary Artery Disease remained the largest indication with 46.50% share in 2024, supported by better acute-coronary-syndrome pathways that lowered 30-day mortality to 4.53%. Dedicated bifurcation stents, imaging-guided PCI, and bioresorbable scaffolds are expanding quickly and enjoy rapid regulatory clearance, reflecting convergence between domestic quality systems and global best practice. As urbanisation and risk-factor prevalence persist, procedure counts should continue rising, anchoring the China cardiovascular devices market size for this application.

Structural and Congenital Heart Defects are forecast to post a 7.14% CAGR, the fastest among clinical segments. Transcatheter heart valves spearhead growth: Jenscare’s Ken-Valve and LuX-Valve Plus target tricuspid and aortic lesions, with design tweaks suited to Chinese anatomical profiles. Clinical-talent shortfalls keep procedure volumes below potential, yet training alliances and tele-proctoring are easing diffusion. As devices migrate from tertiary hubs to provincial centers, adoption velocity should accelerate, adding incremental weight to the China cardiovascular devices market share of structural indications.

By End-User: Home care settings disrupt hospital dominance

Hospitals and cardiac centers controlled 72.49% of the China cardiovascular devices market in 2024, largely due to DRG-linked reimbursement that bundles implants within inpatient episodes. Over 96 TAVR cases were handled at single top-tier sites last year, evidencing procedural concentration. Despite this grip, payment reforms and digital-health incentives are nudging providers toward ambulatory and post-discharge monitoring pathways, slightly diluting hospital hold going forward.

Home care and remote programs are slated for a 6.78% CAGR, driven by smartphone penetration and AI-supported triage that shortens clinic queues. Portable ECG patches, cloud-linked blood-pressure cuffs, and app-based medication reminders enable chronic-care decentralisation. Pilot data show virtual consultations reduce follow-up visits by 18% and maintain anticoagulation adherence above 85%, outlining clear efficiency gains for payers. These shifts support a steady rise in the China cardiovascular devices market contribution from consumer-oriented form factors.

China Cardiovascular Devices Market: Market Share by End User
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

Regional disparities define market opportunity contours. Eastern provinces cluster chest-pain centers that clock door-to-balloon times as low as 51 minutes, driving dense demand for PCI catheters and drug-eluting stents . Around 100 hospitals now offer TAVR, mainly along the coast, underpinning a geographically skewed China cardiovascular devices market share for structural products.

Central and western provinces display rising adoption curves as provincial health budgets fund cath-lab builds and tele-cardiology links. In Ningxia, chest-pain-center adoption cut 3-year mortality from 11.86% to 8.55%, shining light on latent device needs . Tele-ECG and remote diagnosis shrink onset-to-wire intervals, providing footholds for cost-efficient monitoring and imaging solutions. Government equalisation grants are earmarked for 200 additional cath-lab certifications by 2027, which will broaden the China cardiovascular devices market base beyond first-tier cities.

Manufacturing footprints follow similar geography. Shanghai positions itself as a medical-AI capital by 2027, hosting several cardiovascular-robotics pilots[2]Source: Merics, “Lab Leader, Market Ascender: China’s Rise in Biotechnology,” merics.org . Procurement rules that restrict imports in public tenders drive both multinationals and local start-ups to set up plants in Jiangsu and Guangdong, accelerating supply-chain localisation. As domestic assembly scales, lead times fall and after-sales networks tighten, reinforcing regional loyalty and enlarging the total China cardiovascular devices market.

Competitive Landscape

Competition intensifies as domestic R&D spend rises. MicroPort, Lepu Medical, and Venus Medtech funnel 11-14% of revenue into innovation, spawning home-grown iterations of drug-coated balloons and renal-denervation systems . Local players now meet or exceed global standards in coating durability, polymer science, and delivery-shaft flexibility, shrinking multinationals’ technology premium. Policies favouring local provenance further tip tenders in their favour.

Multinationals recalibrate. Medtronic localised production and secured renal-denervation approval in 2024, preserving relevance in hypertension therapy . Johnson & Johnson’s deal to buy Shockwave Medical broadens intravascular lithotripsy access for heavily calcified lesions, a growing need in Chinese patient profiles . Boston Scientific divested its vascular business to refocus on higher-margin rhythm management, signalling portfolio optimisation under pricing pressure.

Innovation keeps reshaping the chessboard. NMPA cleared the first domestic PFA catheter for atrial-fibrillation ablation in 2024, potentially leapfrogging thermal approaches on safety. Mag-lev pumps, bioresorbable scaffolds, and AI-driven decision-support suites are next-wave differentiators. Companies that blend local evidence with cost-efficient engineering stand best positioned to capture share in the evolving China cardiovascular devices market.

China Cardiovascular Devices Industry Leaders

  1. Abbott Laboratories

  2. Boston Scientific Corporation

  3. Medtronic PLC

  4. Lepu Medical Technology(Beijing)Co.,Ltd.

  5. Terumo Corporation

  6. *Disclaimer: Major Players sorted in no particular order
china CVD devices market concentration.png
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • May 2025: Jenscare launched the Ken-Valve TAVR system after NMPA approval, targeting rapid capture of the domestic valve-replacement segment
  • May 2024: Medtronic secured NMPA clearance for the Symplicity Spyral renal-denervation platform, the first such therapy approved for hypertension in China

Table of Contents for China Cardiovascular Devices Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rapid Expansion of China’s Chest-Pain Centers Accrediting Advanced Interventional Device Adoption
    • 4.2.2 Government “Made in China 2025” Initiatives Boosting Domestic Cardiovascular Device Innovation
    • 4.2.3 Rising Prevalence of Atrial Fibrillation in Aging Chinese Population Elevating Demand for CRM Devices
    • 4.2.4 National Volume-Based Procurement (VBP) for Drug-Eluting Stents Triggering High-Volume Domestic Production
    • 4.2.5 Accelerated Conditional Approval Pathway for Breakthrough Cardiovascular Implants by NMPA
  • 4.3 Market Restraints
    • 4.3.1 Price Erosion due to Ongoing VBP Rounds on High-Value Consumables
    • 4.3.2 Capacity Bottlenecks in Qualified Cath Labs Outside Top-Tier Cities
    • 4.3.3 Clinical Talent Shortage for TAVR and Left Atrial Appendage Closure Procedures
    • 4.3.4 Heightened Post-Market Surveillance Scrutiny on Imported Implantables
  • 4.4 Supply-Chain Analysis
  • 4.5 Regulatory Outlook
  • 4.6 Technological Outlook
  • 4.7 Porter’s Five Forces
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Suppliers
    • 4.7.3 Bargaining Power of Buyers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Industry Rivalry
  • 4.8 Pricing Analysis

5. Market Size & Growth Forecasts (Value, USD Billion)

  • 5.1 By Device Type
    • 5.1.1 By Product Type
    • 5.1.1.1 Diagnostic & Monitoring Devices
    • 5.1.1.1.1 ECG Systems
    • 5.1.1.1.2 Remote Cardiac Monitor
    • 5.1.1.1.3 Cardiac MRI
    • 5.1.1.1.4 Cardiac CT
    • 5.1.1.1.5 Echocardiography / Ultrasound
    • 5.1.1.1.6 Fractional Flow Reserve (FFR) Systems
    • 5.1.1.2 Therapeutic & Surgical Devices
    • 5.1.1.2.1 Coronary Stents
    • 5.1.1.2.1.1 Drug-Eluting Stents
    • 5.1.1.2.1.2 Bare-Metal Stents
    • 5.1.1.2.1.3 Bioresorbable Stents
    • 5.1.1.2.2 Catheters
    • 5.1.1.2.2.1 PTCA Balloon Catheters
    • 5.1.1.2.2.2 IVUS/OCT Catheters
    • 5.1.1.2.3 Cardiac Rhythm Management
    • 5.1.1.2.3.1 Pacemakers
    • 5.1.1.2.3.2 Implantable Cardioverter Defibrillators
    • 5.1.1.2.3.3 Cardiac Resynchronization Therapy Devices
    • 5.1.1.2.4 Heart Valves
    • 5.1.1.2.4.1 TAVR/TAVI
    • 5.1.1.2.4.2 Mechanical Valves
    • 5.1.1.2.4.3 Tissue/Bioprosthetic Valves
    • 5.1.1.2.5 Ventricular Assist Devices
    • 5.1.1.2.6 Artificial Hearts
    • 5.1.1.2.7 Grafts & Patches
    • 5.1.1.2.8 Other Cardiovascular Surgical Devices
    • 5.1.2 By Application
    • 5.1.2.1 Coronary Artery Disease
    • 5.1.2.2 Arrhythmia & Conduction Disorders
    • 5.1.2.3 Heart Failure & Cardiomyopathy
    • 5.1.2.4 Structural & Congenital Heart Defects
    • 5.1.2.5 Peripheral Vascular Disease
    • 5.1.3 By End User
    • 5.1.3.1 Hospitals & Cardiac Centres
    • 5.1.3.2 Ambulatory Surgical Centres
    • 5.1.3.3 Cardiology/EP Clinics
    • 5.1.3.4 Home-care & Remote Monitoring Programs

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 MicroPort Scientific Corporation
    • 6.3.2 Lepu Medical Technology (Beijing) Co., Ltd.
    • 6.3.3 Abbott Laboratories
    • 6.3.4 Medtronic plc
    • 6.3.5 Boston Scientific Corporation
    • 6.3.6 Edwards Lifesciences Corporation
    • 6.3.7 Terumo Corporation
    • 6.3.8 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • 6.3.9 Shanghai MicroPort Endovascular MedTech (EMT)
    • 6.3.10 Biotronik SE & Co. KG
    • 6.3.11 Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
    • 6.3.12 Sino Medical Sciences Technology Inc. (SMST)
    • 6.3.13 JW Medical Systems Ltd.
    • 6.3.14 Peijia Medical Limited
    • 6.3.15 Venus Medtech (Hangzhou) Inc.
    • 6.3.16 Kewei Medical Instrument Co., Ltd.
    • 6.3.17 Jiangsu Yuyue Medical Instruments Co., Ltd.

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

China Cardiovascular Devices Market Report Scope

As per the scope of the report, cardiovascular devices are used to diagnose and treat heart disease and related health problems. Also, cardiovascular devices regulate heart rhythm abnormalities and irregular heartbeat which are two major examples of irregularities caused by the heart. The China Cardiovascular Devices Market is segmented by Diagnostic and Monitoring Devices (Electrocardiogram (ECG), Remote Cardiac Monitoring and Other Diagnostic and Monitoring Devices) and Therapeutic and Surgical Devices (Cardiac Assist Devices, Cardiac Rhythm Management Devices, Catheter, Grafts, Heart Valves, Stents and Other Therapeutic and Surgical Devices). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Device Type By Product Type Diagnostic & Monitoring Devices ECG Systems
Remote Cardiac Monitor
Cardiac MRI
Cardiac CT
Echocardiography / Ultrasound
Fractional Flow Reserve (FFR) Systems
Therapeutic & Surgical Devices Coronary Stents Drug-Eluting Stents
Bare-Metal Stents
Bioresorbable Stents
Catheters PTCA Balloon Catheters
IVUS/OCT Catheters
Cardiac Rhythm Management Pacemakers
Implantable Cardioverter Defibrillators
Cardiac Resynchronization Therapy Devices
Heart Valves TAVR/TAVI
Mechanical Valves
Tissue/Bioprosthetic Valves
Ventricular Assist Devices
Artificial Hearts
Grafts & Patches
Other Cardiovascular Surgical Devices
By Application Coronary Artery Disease
Arrhythmia & Conduction Disorders
Heart Failure & Cardiomyopathy
Structural & Congenital Heart Defects
Peripheral Vascular Disease
By End User Hospitals & Cardiac Centres
Ambulatory Surgical Centres
Cardiology/EP Clinics
Home-care & Remote Monitoring Programs
By Device Type
By Product Type Diagnostic & Monitoring Devices ECG Systems
Remote Cardiac Monitor
Cardiac MRI
Cardiac CT
Echocardiography / Ultrasound
Fractional Flow Reserve (FFR) Systems
Therapeutic & Surgical Devices Coronary Stents Drug-Eluting Stents
Bare-Metal Stents
Bioresorbable Stents
Catheters PTCA Balloon Catheters
IVUS/OCT Catheters
Cardiac Rhythm Management Pacemakers
Implantable Cardioverter Defibrillators
Cardiac Resynchronization Therapy Devices
Heart Valves TAVR/TAVI
Mechanical Valves
Tissue/Bioprosthetic Valves
Ventricular Assist Devices
Artificial Hearts
Grafts & Patches
Other Cardiovascular Surgical Devices
By Application Coronary Artery Disease
Arrhythmia & Conduction Disorders
Heart Failure & Cardiomyopathy
Structural & Congenital Heart Defects
Peripheral Vascular Disease
By End User Hospitals & Cardiac Centres
Ambulatory Surgical Centres
Cardiology/EP Clinics
Home-care & Remote Monitoring Programs
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current value of the China cardiovascular devices market?

The market is valued at USD 3.16 billion in 2025 and is forecast to reach USD 4.19 billion by 2030.

Which device category leads market revenue?

Therapeutic and Surgical Devices make up 68.20% of total revenue as of 2024.

Which segment is growing fastest?

Diagnostic and Monitoring Devices are projected to advance at a 6.98% CAGR through 2030.

How is policy affecting pricing?

Volume-based procurement cut stent prices by 95% and is extending to pacemakers, valves, and defibrillators, reshaping pricing across categories.

Page last updated on: June 26, 2025

China Cardiovascular Devices Market Report Snapshots